From: Treatment modalities and drug survival in a systemic sclerosis real-life patient cohort
Total (n = 497) | Diffuse (n = 243) | Limited (n = 254) | p | |
---|---|---|---|---|
Immunosuppresives/ antiproliferatives | ||||
Methotrexate | 265 (53%) | 134 (55%) | 131 (52%) | NS |
Cyclophosphamide | 130 (26%) | 97 (40%) | 33 (13%) | 0.021 |
Mycophenolate | 58 (12%) | 36 (15%) | 22 (9%) | 0.068 |
Azathiorine | 52 (10.5%) | 27 (11%) | 25 (10%) | NS |
Rituximab | 43 (9%) | 34 (14%) | 9 (4%) | 0.001 |
Tocilizumab | 25 (5%) | 14 (6%) | 11 (4%) | NS |
Vasoactives | ||||
Calcium channel blockers | 338 (68%) | 172 (71%) | 166 (65%) | NS |
Bosentan | 164 (33%) | 104 (43%) | 60 (24%) | 0.001 |
Abrisentan | 13 (3%) | 7 (3%) | 6 (2%) | NS |
Macitentan | 9 (2%) | 3 (1%) | 6 (2%) | NS |
Sildenafil | 34 (7%) | 23 (9%) | 11 (4%) | 0.05 |
Iloprost | 33 (7%) | 18 (7%) | 15 (6%) | NS |
Only immunosuppressive treatment | 209 (42%) | 96 (40%) | 113 (45%) | NS |
Only vasoactive treatment | 39 (8%) | 20 (8%) | 19 (7%) | NS |
Both treatments | 156 (31%) | 102 (42%) | 54 (21%) | 0.001 |
No treatment | 93 (19%) | 25 (10%) | 68 (27%) | 0.001 |